Actionable news
All posts from Actionable news
Actionable news in SLP: Simulations Plus, Inc.,

Simulations Plus Investor Relations Hayden IR Ms. Renee Bouche Mr. Cameron Donahue

The following excerpt is from the company's SEC filing.



For Immediate Release:

Simulations Plus to Launch Major New Software Product

PKPlus™ Will Provide Analysis Capability Required for Regulatory Submissions

LANCASTER, CA, October 15, 2015 –

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced it is expanding its offerings of best-in-class software for pharmaceutical research and development with PKPlus™, a new pro gram that provides high-quality, user-friendly analysis and reporting of clinical trial data for use in submissions to regulatory agencies.

John DiBella, vice president for marketing and sales for Simulations Plus, said: “We believe PKPlus represents a major addition to our product line with the potential to become one of our leading sources of revenues and earnings. Many in the industry have been under the mistaken impression that there is only one software program that meets the requirements of regulatory agencies for analysis and reporting of noncompartmental analysis results for clinical trial data. We intend to correct that misconception. We have taken the core elements of our PKPlus Module, originally introduced as an optional module in our flagship


software over 15 years ago, and are turning it into a standalone program that will provide:

calculation of pharmacokinetic parameters using noncompartmental analysis,

calculation of pharmacokinetic parameters using compartmental analysis with 1, 2, or 3 compartments,

support for importing and...